MannKind Corp (MNKD) - Total Liabilities
Based on the latest financial reports, MannKind Corp (MNKD) has total liabilities worth $803.60 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MannKind Corp annual equity growth to track the company's year-over-year net asset growth rate.
MannKind Corp - Total Liabilities Trend (2000–2025)
This chart illustrates how MannKind Corp's total liabilities have evolved over time, based on quarterly financial data. See MannKind Corp free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
MannKind Corp Competitors by Total Liabilities
The table below lists competitors of MannKind Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sixt SE
XETRA:SIX3
|
Germany | €5.56 Billion |
|
Sansteel MinGuang Co Ltd Fujian
SHE:002110
|
China | CN¥32.65 Billion |
|
Shandong Hi-Speed Road&Bridge
SHE:000498
|
China | CN¥135.60 Billion |
|
Jinzi Ham Co Ltd
SHE:002515
|
China | CN¥94.13 Million |
|
Collective Mining Ltd
TO:CNL
|
Canada | CA$12.92 Million |
|
Godrej Agrovet Limited
NSE:GODREJAGRO
|
India | Rs40.07 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥2.53 Billion |
|
Gelex Group JSC
VN:GEX
|
Vietnam | ₫53.08 Trillion |
Liability Composition Analysis (2000–2025)
This chart breaks down MannKind Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is MannKind Corp worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -13.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MannKind Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MannKind Corp (2000–2025)
The table below shows the annual total liabilities of MannKind Corp from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $843.20 Million | +78.40% |
| 2024-12-31 | $472.66 Million | -34.48% |
| 2023-12-31 | $721.37 Million | +32.16% |
| 2022-12-31 | $545.82 Million | +2.89% |
| 2021-12-31 | $530.51 Million | +83.55% |
| 2020-12-31 | $289.03 Million | +1.68% |
| 2019-12-31 | $284.25 Million | +0.52% |
| 2018-12-31 | $282.79 Million | -5.52% |
| 2017-12-31 | $299.31 Million | +2.98% |
| 2016-12-31 | $290.66 Million | -39.03% |
| 2015-12-31 | $476.75 Million | +1.82% |
| 2014-12-31 | $468.21 Million | +61.81% |
| 2013-12-31 | $289.36 Million | -20.07% |
| 2012-12-31 | $361.99 Million | -29.46% |
| 2011-12-31 | $513.21 Million | +10.89% |
| 2010-12-31 | $462.79 Million | +50.93% |
| 2009-12-31 | $306.62 Million | +56.66% |
| 2008-12-31 | $195.72 Million | +9.13% |
| 2007-12-31 | $179.34 Million | +14.78% |
| 2006-12-31 | $156.25 Million | +630.34% |
| 2005-12-31 | $21.39 Million | +63.06% |
| 2004-12-31 | $13.12 Million | -8.25% |
| 2003-12-31 | $14.30 Million | +2.14% |
| 2002-12-31 | $14.00 Million | +30.17% |
| 2000-12-31 | $10.76 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more